Newsroom

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Fortune's World's Best Workplaces™ list for the second consecutive year, recognizing the...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in fireside chats at three upcoming healthcare conferences. The UBS Global Biopharma...

Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX®...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that on November 2, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and...

Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the...

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report third-quarter 2026 financial results on Thursday, November 5, 2026. Company executives will host a...